A new platform for high-throughput therapy testing on iPSC-derived lung progenitor cells from cystic fibrosis patients

For those people with cystic fibrosis carrying rare CFTR mutations not responding to currently available therapies, there is an unmet need for relevant tissue models for therapy development. Here, we describe a new testing platform that employs patient-specific induced pluripotent stem cells (iPSCs)...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Jia Xin, Wellhauser, Leigh, Laselva, Onofrio, Utkina, Irina, Bozoky, Zoltan, Gunawardena, Tarini, Ngan, Zoe, Xia, Sunny, Di Paola, Michelle, Eckford, Paul D.W., Ratjen, Felix, Moraes, Theo J., Parkinson, John, Wong, Amy P., Bear, Christine E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Resource
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8581165/
https://www.ncbi.nlm.nih.gov/pubmed/34678210
http://dx.doi.org/10.1016/j.stemcr.2021.09.020

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8581165/
https://www.ncbi.nlm.nih.gov/pubmed/34678210
http://dx.doi.org/10.1016/j.stemcr.2021.09.020

Ejemplares similares